GDF15: a potential therapeutic target for type 1 diabetes

dc.contributor.authorSarkar, Soumyadeep
dc.contributor.authorMelchior, John T.
dc.contributor.authorHenry, Hayden R.
dc.contributor.authorSyed, Farooq
dc.contributor.authorMirmira, Raghavendra G.
dc.contributor.authorNakayasu, Ernesto S.
dc.contributor.authorMetz, Thomas O.
dc.contributor.departmentPediatrics, School of Medicine
dc.date.accessioned2023-10-30T08:53:56Z
dc.date.available2023-10-30T08:53:56Z
dc.date.issued2022-01
dc.description.abstractIntroduction: Current treatment for type 1 diabetes (T1D) is centered around insulin supplementation to manage the effects of pancreatic β cell loss. GDF15 is a potential preventative therapy against T1D progression that could work to curb increasing disease incidence. Areas covered: This paper discusses the known actions of GDF15, a pleiotropic protein with metabolic, feeding, and immunomodulatory effects, connecting them to highlight the open opportunities for future research. The role of GDF15 in the prevention of insulitis and protection of pancreatic β cells against pro-inflammatory cytokine-mediated cellular stress are examined and the pharmacological promise of GDF15 and critical areas of future research are discussed. Expert opinion: GDF15 shows promise as a potential intervention but requires further development. Preclinical studies have shown poor efficacy, but this result may be confounded by the measurement of gross GDF15 instead of the active form. Additionally, the effect of GDF15 in the induction of anorexia and nausea-like behavior and short-half-life present significant challenges to its deployment, but a systems pharmacology approach paired with chronotherapy may provide a possible solution to therapy for this currently unpreventable disease.
dc.eprint.versionAuthor's manuscript
dc.identifier.citationSarkar S, Melchior JT, Henry HR, et al. GDF15: a potential therapeutic target for type 1 diabetes. Expert Opin Ther Targets. 2022;26(1):57-67. doi:10.1080/14728222.2022.2029410
dc.identifier.urihttps://hdl.handle.net/1805/36757
dc.language.isoen_US
dc.publisherTaylor & Francis
dc.relation.isversionof10.1080/14728222.2022.2029410
dc.relation.journalExpert Opinion on Therapeutic Targets
dc.rightsPublisher Policy
dc.sourcePMC
dc.subjectType 1 diabetes (T1D)
dc.subjectType 2 diabetes (T2D)
dc.subjectGDF15
dc.subjectInsulitis
dc.subjectβ cells stress
dc.subjectER stress
dc.subjectImmunomodulator & chronotherapy
dc.titleGDF15: a potential therapeutic target for type 1 diabetes
dc.typeArticle
Files
Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
nihms-1776500.pdf
Size:
1.13 MB
Format:
Adobe Portable Document Format
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.99 KB
Format:
Item-specific license agreed upon to submission
Description: